Harvard Bioscience Analyst Ratings
Harvard Bioscience Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2022 | 106.61% | Keybanc | $7 → $5 | Maintains | Overweight |
| 08/05/2022 | 189.26% | Keybanc | $10 → $7 | Maintains | Overweight |
| 11/10/2020 | 147.93% | Keybanc | → $6 | Initiates Coverage On | → Overweight |
| 02/27/2020 | 65.29% | Benchmark | $3.5 → $4 | Maintains | Speculative Buy |
| 日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/09/2022 | 106.61% | Keybanc | 7 美元 → 5 美元 | 維護 | 超重 |
| 08/05/2022 | 189.26% | Keybanc | 10 美元 → 7 美元 | 維護 | 超重 |
| 11/10/2020 | 147.93% | Keybanc | → 6 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 02/27/2020 | 65.29% | 基準 | 3.5 美元 → 4 美元 | 維護 | 投機性買入 |
Harvard Bioscience Questions & Answers
哈佛生物科學問題與解答
The latest price target for Harvard Bioscience (NASDAQ: HBIO) was reported by Keybanc on November 9, 2022. The analyst firm set a price target for $5.00 expecting HBIO to rise to within 12 months (a possible 106.61% upside). 2 analyst firms have reported ratings in the last year.
Keybanc於2022年11月9日公佈了哈佛生物科學（納斯達克股票代碼：HBIO）的最新目標股價。該分析公司將目標股價定爲5.00美元，預計HBIO將在12個月內上漲至5美元（可能上漲106.61％）。去年有兩家分析公司公佈了評級。
The latest analyst rating for Harvard Bioscience (NASDAQ: HBIO) was provided by Keybanc, and Harvard Bioscience maintained their overweight rating.
哈佛生物科學（納斯達克股票代碼：HBIO）的最新分析師評級由Keybanc提供，哈佛生物科學維持其增持評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Harvard Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Harvard Bioscience was filed on November 9, 2022 so you should expect the next rating to be made available sometime around November 9, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與哈佛生物科學的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。哈佛生物科學的最新評級是在2022年11月9日提交的，因此您應該預計下一個評級將在2023年11月9日左右公佈。
While ratings are subjective and will change, the latest Harvard Bioscience (HBIO) rating was a maintained with a price target of $7.00 to $5.00. The current price Harvard Bioscience (HBIO) is trading at is $2.42, which is out of the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但哈佛生物科學（HBIO）的最新評級維持不變，目標股價爲7.00美元至5.00美元。哈佛生物科學（HBIO）目前的交易價格爲2.42美元，超出了分析師的預測區間。